NCT03951207

Rosuvastatin/Amlodipine vs Atorvastatin/Amlodipine in Hypertension Patient With Dyslipidemia

Randomized, Multicenter, Parallel, Open, Phase 4 Study to Compare the Efficacy and Safety of Rosuvastatin/Amlodipine Combination Therapy Versus Atorvastatin/Amlodipine Combination Therapy in Hypertension Patient With Dyslipidemia

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 259 (actual)
• Sponsor: Yuhan Corporation · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

This study is to Compare the Efficacy and Safety of Rosuvastatin/Amlodipine Combination Therapy Versus Atorvastatin/Amlodipine Combination Therapy in Hypertension patient with Dyslipidemia

Conditions

• Dyslipidemias
• Hypertension

Interventions

Type	Name	Description
DRUG	Rosuampin 10/5mg	Rosuvastatin 10mg/Amlodipine 5mg qd for 8 weeks
DRUG	Rosuampin 20/5mg	Rosuampin 20/5mg qd for 8 weeks
DRUG	Amlodipine/Atorvastatin 5/20mg	Amlodipine/Atorvastatin 5/20mg qd for 8 weeks

Timeline

• Start date: 2019-05-30
• Primary completion: 2021-09-29
• Completion: 2021-09-29
• First posted: 2019-05-15
• Last updated: 2022-10-12

Locations

1 site across 1 country: South Korea